Thanks bmfjch........but I think maybe the CEO's response, and in fact the question, referred to the next readout for the GBM Trial. Not sure, but here is actual question from Bidget. Certainly in the audio, I did think Bridget was talking about GBM data.
Nice to hear, all the funds apparently liked the data. (Questions did not inspire me though, far better discussion here.) These bigger players to a big degree are calling the shots on the SP. As I mentioned though, there are some big players on this chatline....who have never heard of KZ. So shhall keep posting and highlight the fact in a FDA Phase 3 for GBM @ cap of US130m --- CRAZY
_____________
Bridget Wilson: (Oakwood Trust, Analyst) Thank you. And congratulations, as some of the callers have said, James this data is looking really good. I may have missed it, but I’ve got two questions actually. The first one is just could you talk to where you expect to see the next data readouts on the trial? Then after that I’ve got one about funding.
KZA Price at posting:
$1.41 Sentiment: Buy Disclosure: Held
